ERBB2 and glioblastoma: Given the high prevalence of EGFR and ERBB2 amplification/overexpression in GBM patients and the unique EGFRvIII mutation that occurs in tumors rather than normal brain, EGFR and its mutants have been attractive targets for developing GBM treatments (Table 1).